Jump to content

CP-615,003

From Wikipedia, the free encyclopedia
CP-615,003
Identifiers
  • N-(3-fluoro-4-(2-(propylamino)ethoxy)phenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H24FN3O3
Molar mass373.428 g·mol−1
3D model (JSmol)
  • O=C(NC1=CC=C(OCCNCCC)C(F)=C1)C2=CNC3=C2C(CCC3)=O
  • InChI=1S/C20H24FN3O3/c1-2-8-22-9-10-27-18-7-6-13(11-15(18)21)24-20(26)14-12-23-16-4-3-5-17(25)19(14)16/h6-7,11-12,22-23H,2-5,8-10H2,1H3,(H,24,26) ☒N
  • Key:YZHJISPIBWKWGY-UHFFFAOYSA-N ☒N
  (verify)

CP-615,003 is a drug which acts as a subtype-selective partial agonist at GABAA receptors, and was developed by Pfizer as a potential anxiolytic; however, poor blood–brain barrier penetration make it primarily useful as a research ligand.[1][2]

References

[edit]
  1. ^ Shaffer CL, Gunduz M, O'Connell TN, Obach RS, Yee S (November 2005). "Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolites". Drug Metabolism and Disposition. 33 (11): 1688–99. doi:10.1124/dmd.105.004630. PMID 16081672. S2CID 6983318.
  2. ^ Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA (August 2007). "Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures". Drug Metabolism and Disposition. 35 (8): 1341–9. doi:10.1124/dmd.106.013953. PMID 17470526. S2CID 32926420.
Stub icon

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CP-615,003&oldid=1190948637"